DK1208104T3 - Tricykliske inhibitorer af poly(ADP-ribose)polymeraser - Google Patents

Tricykliske inhibitorer af poly(ADP-ribose)polymeraser

Info

Publication number
DK1208104T3
DK1208104T3 DK00961437T DK00961437T DK1208104T3 DK 1208104 T3 DK1208104 T3 DK 1208104T3 DK 00961437 T DK00961437 T DK 00961437T DK 00961437 T DK00961437 T DK 00961437T DK 1208104 T3 DK1208104 T3 DK 1208104T3
Authority
DK
Denmark
Prior art keywords
polymerases
adp
ribose
poly
tricyclic inhibitors
Prior art date
Application number
DK00961437T
Other languages
Danish (da)
English (en)
Inventor
Stephen Evan Webber
Donald James Skalitzky
Joseph Timothy Marakovits
Walter Brian Eastman
Jayashree Girish Tikhe
Robert Arnold Kumpf
Original Assignee
Agouron Pharma
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma, Cancer Rec Tech Ltd filed Critical Agouron Pharma
Application granted granted Critical
Publication of DK1208104T3 publication Critical patent/DK1208104T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00961437T 1999-08-31 2000-08-31 Tricykliske inhibitorer af poly(ADP-ribose)polymeraser DK1208104T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15214299P 1999-08-31 1999-08-31
PCT/US2000/023882 WO2001016136A2 (en) 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose) polymerases

Publications (1)

Publication Number Publication Date
DK1208104T3 true DK1208104T3 (da) 2005-05-02

Family

ID=22541675

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00961437T DK1208104T3 (da) 1999-08-31 2000-08-31 Tricykliske inhibitorer af poly(ADP-ribose)polymeraser

Country Status (48)

Country Link
US (1) US6548494B1 (de)
EP (1) EP1208104B1 (de)
JP (1) JP4272375B2 (de)
KR (1) KR20020038742A (de)
CN (1) CN1384835A (de)
AP (1) AP1553A (de)
AR (1) AR035162A1 (de)
AT (1) ATE287406T1 (de)
AU (1) AU781826B2 (de)
BG (1) BG106562A (de)
BR (1) BR0015051A (de)
CA (1) CA2382404C (de)
CO (1) CO5200769A1 (de)
CR (1) CR6577A (de)
CZ (1) CZ2002613A3 (de)
DE (1) DE60017575T2 (de)
DK (1) DK1208104T3 (de)
DO (1) DOP2000000069A (de)
DZ (1) DZ3216A1 (de)
EA (1) EA200200306A1 (de)
EC (1) ECSP003637A (de)
EE (1) EE200200100A (de)
ES (1) ES2234657T3 (de)
GE (1) GEP20043268B (de)
GT (1) GT200000145A (de)
HK (1) HK1045509B (de)
HR (1) HRP20020271A2 (de)
HU (1) HUP0202703A3 (de)
IL (1) IL147863A0 (de)
IS (1) IS6289A (de)
MA (1) MA25876A1 (de)
MX (1) MXPA02002138A (de)
MY (1) MY135910A (de)
NO (1) NO322475B1 (de)
NZ (1) NZ516793A (de)
OA (1) OA12016A (de)
PA (1) PA8501801A1 (de)
PE (1) PE20010538A1 (de)
PL (1) PL354242A1 (de)
PT (1) PT1208104E (de)
SI (1) SI1208104T1 (de)
SK (1) SK2592002A3 (de)
SV (1) SV2003000162A (de)
UA (1) UA73144C2 (de)
UY (1) UY26323A1 (de)
WO (1) WO2001016136A2 (de)
YU (1) YU15102A (de)
ZA (1) ZA200200830B (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
EP1183259A2 (de) * 1999-09-28 2002-03-06 Basf Aktiengesellschaft Azepinoindol-derivate, deren herstellung und anwendung
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
WO2003051879A1 (en) * 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
WO2003103666A2 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
JP3990718B2 (ja) 2003-01-09 2007-10-17 ファイザー・インク キナーゼ阻害剤としてのジアゼピノインドール誘導体
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7531530B2 (en) * 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
WO2005035534A1 (ja) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
PL2305221T3 (pl) * 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
PT1794163E (pt) * 2004-09-22 2010-03-01 Pfizer Método para a preparação de inibidores de poli(adpribose)- polimerases
US7820668B2 (en) * 2005-01-19 2010-10-26 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
AR053902A1 (es) 2005-06-14 2007-05-23 Schering Corp Inhibidores de aspartil proteasa heterociclicos macrociclicos
WO2006137510A1 (ja) 2005-06-24 2006-12-28 Ono Pharmaceutical Co., Ltd. 脳血管障害時における出血低減剤
ZA200800907B (en) * 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
US20070032469A1 (en) * 2005-08-05 2007-02-08 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
JP2010504079A (ja) * 2006-06-12 2010-02-12 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤を用いる疾病の治療方法
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CN101534836B (zh) * 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
AU2008258599B2 (en) 2007-06-05 2013-06-13 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
EP2217244A4 (de) * 2007-11-12 2011-08-31 Bipar Sciences Inc Behandlung von gebärmutterkrebs und eierstockkrebs mit einem parp-inhibitor allein oder in kombination mit antitumoralen mitteln
US7732491B2 (en) * 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
RU2010128107A (ru) * 2007-12-07 2012-01-20 Байпар Сайенсиз, Инк. (Us) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
MX2010008572A (es) * 2008-02-04 2010-11-30 Bipar Sciences Inc Metodos de diagnostico y tratamiento de enfermedades mediadas por poli(adp-ribosa) polimerasa.
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2737400C (en) 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
WO2014037313A1 (de) * 2012-09-05 2014-03-13 Bayer Cropscience Ag Verwendung substituierter benzodiazepinone und benzazepinone oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
CA2935857C (en) * 2014-01-05 2020-12-15 Washington University Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
RU2019114863A (ru) 2016-11-02 2020-12-03 Иммуноджен, Инк. Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
US11535633B2 (en) 2018-06-28 2022-12-27 Jiangsu Hengrui Medicine Co., Ltd. Fused tricyclic heterocycle compounds and therapeutic uses thereof
AU2019326633B2 (en) * 2018-08-24 2022-09-08 Adlai Nortye Biopharma Co., Ltd. High activity sting protein agonist
US20220056044A1 (en) * 2018-12-14 2022-02-24 Jiangsu Hengrui Medicine Co., Ltd. Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof
CN113365998B (zh) * 2019-02-02 2023-04-14 正大天晴药业集团股份有限公司 用于parp抑制剂的吲哚并七元酰肟类似物
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230234938A1 (en) 2020-04-28 2023-07-27 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CN116940691A (zh) 2021-01-08 2023-10-24 赛博克萨2公司 用于制备缀合物连接部分的方法
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase
US20250154115A1 (en) * 2022-02-11 2025-05-15 The University Of North Carolina At Chapel Hill Arylbenzoisoxazole compounds as ip6k and ipmk inhibitors and methods of use thereof
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合
WO2025106920A1 (en) * 2023-11-15 2025-05-22 Yale University Parp pet imaging agents and methods of using the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052390A (de) 1964-03-24
US3734919A (en) * 1969-11-03 1973-05-22 Upjohn Co 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones
US3642820A (en) * 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
DE2056215A1 (de) 1970-11-16 1972-05-18 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Verfahren zur Herstellung von N-Mono-(beta-Cyanäthyl>anilinen
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE4125292A1 (de) 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
WO1995009159A1 (en) 1993-09-28 1995-04-06 Otsuka Pharmaceutical Company, Limited Quinoxaline derivative as antidiabetic agent
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
EP0841924B1 (de) * 1995-08-02 2002-10-02 Newcastle University Ventures Limited Benzimidazol verbindungen
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
AU7484798A (en) 1997-05-13 1998-12-08 Octamer, Inc. Methods for treating inflammation, inflammatory diseases, arthritis and strok e using padprt inhibitors
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
AU9298798A (en) 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
CA2332279A1 (en) 1998-05-15 1999-11-25 Jia-He Li Carboxamide compounds, compositions, and methods for inhibiting parp activity

Also Published As

Publication number Publication date
YU15102A (sh) 2004-12-31
KR20020038742A (ko) 2002-05-23
UY26323A1 (es) 2001-04-30
NO20020421D0 (no) 2002-01-28
DOP2000000069A (es) 2002-08-30
ECSP003637A (es) 2002-03-25
CZ2002613A3 (cs) 2002-08-14
PL354242A1 (en) 2003-12-29
EP1208104A2 (de) 2002-05-29
AU7338900A (en) 2001-03-26
HRP20020271A2 (en) 2005-12-31
MA25876A1 (fr) 2003-10-01
BG106562A (bg) 2003-03-31
ES2234657T3 (es) 2005-07-01
CR6577A (es) 2003-12-05
PE20010538A1 (es) 2001-05-22
SK2592002A3 (en) 2002-10-08
OA12016A (en) 2006-04-19
SV2003000162A (es) 2003-07-29
DZ3216A1 (fr) 2001-03-08
JP2003513015A (ja) 2003-04-08
EP1208104B1 (de) 2005-01-19
ATE287406T1 (de) 2005-02-15
IS6289A (is) 2002-02-27
HK1045509B (en) 2005-04-29
SI1208104T1 (en) 2005-06-30
HUP0202703A2 (hu) 2002-12-28
EE200200100A (et) 2003-06-16
WO2001016136A3 (en) 2001-06-21
JP4272375B2 (ja) 2009-06-03
NO20020421L (no) 2002-04-25
CO5200769A1 (es) 2002-09-27
AR035162A1 (es) 2004-05-05
CA2382404C (en) 2009-03-24
IL147863A0 (en) 2002-08-14
UA73144C2 (en) 2005-06-15
NO322475B1 (no) 2006-10-09
CN1384835A (zh) 2002-12-11
HK1045509A1 (en) 2002-11-29
GEP20043268B (en) 2004-06-25
WO2001016136B1 (en) 2001-11-15
NZ516793A (en) 2004-03-26
DE60017575T2 (de) 2005-06-09
MXPA02002138A (es) 2003-08-20
GT200000145A (es) 2002-02-21
AU781826B2 (en) 2005-06-16
MY135910A (en) 2008-07-31
DE60017575D1 (de) 2005-02-24
HUP0202703A3 (en) 2004-12-28
US6548494B1 (en) 2003-04-15
WO2001016136A2 (en) 2001-03-08
EA200200306A1 (ru) 2002-08-29
ZA200200830B (en) 2003-03-26
PT1208104E (pt) 2005-04-29
AP1553A (en) 2006-01-18
CA2382404A1 (en) 2001-03-08
BR0015051A (pt) 2002-06-25
PA8501801A1 (es) 2002-08-26

Similar Documents

Publication Publication Date Title
DK1208104T3 (da) Tricykliske inhibitorer af poly(ADP-ribose)polymeraser
EE200100364A (et) Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid
DK1183033T3 (da) Pyrrolotriazininhibitorer af kinaser
DK1064298T3 (da) Inhibitorer af caspaser
DK1438306T3 (da) Derivater af UK-2A
DK0984957T3 (da) Hidtil ukendt form af S-omeprazol
DK1173760T3 (da) Indkodning af mikrobærere
NO20012337D0 (no) Fremgangsmåte for sementering av underjordiske soner
IS5772A (is) Þalazín (phthalazine) afleiður af fosfódíesterasa4 lötum
DK1274427T3 (da) Formulering af substituerede benzimidazoler
DK1187833T3 (da) Fremgangsmåde til fremstilling af thiamethoxam
DK1280803T3 (da) Krystallinsk form II af cabergolin
DK1155050T3 (da) Fremstilling af polyolefin
IS6215A (is) Að mestu leyti kristallað form af melagatrani
IS5155A (is) Fjölgervingur af zópólrestat mónóhýdrati
DK1102747T3 (da) Krystalformer af osenetant
IS6620A (is) Nýr fjölgervingur V af tórasemíði
DK1140984T3 (da) Selektive inhibitorer af MMP-12
NO20021234L (no) Anvendelse av tienopyrimidiner
DK0986939T3 (da) Indretning til plasmabehandling af overflader
DK1227795T3 (da) Lipidkompleks af alkycycliner
DK1191025T3 (da) Krystaller af lansoprazol
DK1133290T3 (da) Anvendelse af acetylcholinesterase-inhibitorer til behandling af delirier
SE9802347D0 (sv) Profilelement av två olika slag
FI4225U1 (fi) Teknisen laitteiston erikoisosa